Characteristic All patients with melanoma (n=23) Patient without Staging (n=2) Patients with Stage 0 (n=3) Patients with Stage I (n=5) Patients with Stage II (n=4) Patients with Stage III (n=9)
Initial Therapy (n=23) WLE & SLNB WLE Immunotherapy 18 (78.3) 5 (21.7) 8 (34.8)
2 (100)
1 (50) 1 (50) 3 (50) 3 (50)
4 (100)
9 (100) 8 (88.9)
Response (n=23) No progression/recurrence Progression Recurrence 21 (91.3) 2 (8.7) 2 (100) 1 (50)
6 (100)
4 (100)
8 (88.9) 1 (11.1)
Margins (n=23)
Positive Negative 9 (39.1) 14 (56.5)
2 (100)
1 (50) 1 (50) 2 (33.3) 4 (66.7) 2 (50) 2 (50) 4 (44.4) 5 (55.6)
Ulceration (n=21) Yes No 3 (13) 18 (78)
1 (50)
2 (100)
6 (100)
1 (25) 3 (75) 2 (22.2) 6 (66.7)
Presence of other melanocytic nevi (n=22)
Yes No 18 (81.8) 4 (18.2)
2 (100)
1 (50)
4 (66.7) 2 (33.3)
4 (100)
7 (77.8) 2 (22.2)
Therapy at progression or recurrence*
Radiation Surgery Immunotherapy 1 (50) 2 (100) 2 (100) 1 (50) 2 (100) 2 (100)
History of sunburns (n=23)
Yes No 6 (26.1) 17 (73.9) 1 (50) 1 (50)
3 (100)
1 (20) 4 (80) 2 (50) 2 (50) 2 (22.2) 7 (77.8)
Family history of melanoma (n=23)
Yes No 6 (26.1) 17 (73.9)
2 (100)
1 (50) 1 (50) 2 (33.3) 4 (66.7) 1 (25) 3 (75) 2 (22.2) 7 (77.8)
Family history of dysplastic nevi syndrome (n=23)
Yes No 1 (4.3) 22 (95.7)
2 (100)
2 (100)
1 (16.7) 5 (83.3)
4 (100)
9 (100)
Positive SLNB (n = 19)
Yes No 11 (47.8) 8 (52.2)
2 (100)
1 (50)
1 (16.7) 2 (40)
4 (100)
9 (100)